<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971954</url>
  </required_header>
  <id_info>
    <org_study_id>HS#2013-9964</org_study_id>
    <secondary_id>1R01AG067073</secondary_id>
    <nct_id>NCT04971954</nct_id>
  </id_info>
  <brief_title>Using Nicotine to Reverse Age-related Auditory Processing Deficits</brief_title>
  <acronym>Nicotine</acronym>
  <official_title>Using Nicotine to Reverse Age-related Auditory Processing Deficits: Human Psychophysics and Electrophysiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will evaluate the effects of both aging and nicotine on psychophysical&#xD;
      tasks and electrophysiological measures. Nicotine will be administered to study participants&#xD;
      in the form of gum that is available as an over-the-counter medication. The hypothesis is&#xD;
      that nicotine will reverse the detrimental effects of aging on auditory processing. The&#xD;
      proposed experiments will characterize the effects of nicotine and may eventually lead to&#xD;
      improved treatments of hearing loss in a variety of patient populations and in healthy aging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants will be recruited in two age groups: young (18-28 years) and old (60-85).&#xD;
      Each participant will participate in two psychophysical and electrophysiological test&#xD;
      sessions. For each of the two sessions, the participant will be administered gum before the&#xD;
      test. For one of these sessions, the gum will be polacrilex that contains 6-mg nicotine, and&#xD;
      for the other session, the gum will be a placebo control. The study will be double-blind,&#xD;
      meaning that neither the experimenter nor the participant will know whether the participant&#xD;
      has received nicotine or placebo for a given session. The study has a cross-over design,&#xD;
      meaning that all participants will receive both nicotine and placebo in separate sessions.&#xD;
      Finally, the order of drug administration will be counterbalanced, meaning that equal numbers&#xD;
      of participants will receive 1) nicotine in session one and placebo in session two, and 2)&#xD;
      placebo in session one and nicotine in session two.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The nicotine and placebo gums will be administered in randomized, double-blind, counterbalanced fashion.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Nicotine (6 mg) will be administered in the form of polacrilex gum that is available as an over-the-counter medication. The placebo will also be a commercially available gum that resembles the nicotine gum in flavor, size, shape, color, and texture.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hearing thresholds</measure>
    <time_frame>1 hour</time_frame>
    <description>Hearing thresholds in dB SPL will be measured as a function of sound frequency from 125 Hz to 8000 Hz in quiet or in noise.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modulation detection</measure>
    <time_frame>1 hour</time_frame>
    <description>Amplitude-modulated sounds will be presented at 70 dB SPL or a comfortable level. The detection threshold in percent modulation depth (m= 0 to 100) will be recorded and converted into signal-to-noise ratios in dB (=20log(m)).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Envelope following responses</measure>
    <time_frame>2 hours</time_frame>
    <description>Electrophysiological responses will be recorded in response to amplitude or frequency-modulated sounds. The sounds will be presented at 70 dB SPL or a comfortable level. The EEG signal strength that is in synchrony with the modulation frequency in micro-Volts will be recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>10 minutes</time_frame>
    <description>Pulse rate in pulses per minute will be measured via pulse oximetry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood change</measure>
    <time_frame>10 minutes</time_frame>
    <description>Mood change will be measured by a 9-category rating scale including: energy, contentedness, focus, relaxation, calmness, alertness, hunger etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nicotine side effects</measure>
    <time_frame>10 minutes</time_frame>
    <description>Side effects will be rated on a 5-point scale including: 1 = none (no symptoms at all); 2 = mild (slight jitters); 3 = moderate (jittery, slight dull headache); 4 = moderately severe (jittery, dull headache, mild nausea); 5 = severe (jittery, dull or pounding headache, nausea, vomiting).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cognition</measure>
    <time_frame>1 hour</time_frame>
    <description>Word learning, recall and animal fluency tests from the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) will be measured and normalized to the national standard distribution, with a score of 0 equaling to the mean and 1 being one standard deviation above the mean performance.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Auditory Perceptual Impairment</condition>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Nicotine gum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nicotine (6 mg) will be administered in the form of polacrilex gum that is available as an over-the-counter medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo gum</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo will also be a commercially available gum that resembles the nicotine gum in flavor, size, shape, color, and texture.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nicotine gum</intervention_name>
    <description>Nicotine (6 mg) will be administered in the form of polacrilex gum that is available as an over-the-counter medication</description>
    <arm_group_label>Nicotine gum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo gum</intervention_name>
    <description>The placebo will also be a commercially available gum that resembles the nicotine gum in flavor, size, shape, color, and texture.</description>
    <arm_group_label>Placebo gum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  between 18 and 85 years of age&#xD;
&#xD;
          -  non-smokers with a score of 0-2 out of 10 maximum on the Fagerström index of smoking&#xD;
             dependency&#xD;
&#xD;
          -  cognitive performance within two standard deviations of the CERAD mean&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  less than 18 or greater than 85 years of age&#xD;
&#xD;
          -  deafness or excessive hearing loss&#xD;
&#xD;
          -  smokers with a score between 3 and 10 on the Fagerström index of smoking dependency&#xD;
&#xD;
          -  history of psychiatric illness, neurological disorders, diabetes mellitus, renal&#xD;
             failure, or cardiovascular disease&#xD;
&#xD;
          -  regular use of prescription medications (excluding oral contraceptives)&#xD;
&#xD;
          -  drug dependency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fan-Gang Zeng, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Kapolowicz, PhD</last_name>
    <phone>9498249107</phone>
    <email>mkapolow@hs.uci.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hearing and Speech Lab</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michelle Kapolowicz, PhD</last_name>
      <phone>949-824-9107</phone>
      <email>mkapolow@hs.uci.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pham CQ, Kapolowicz MR, Metherate R, Zeng FG. Nicotine enhances auditory processing in healthy and normal-hearing young adult nonsmokers. Psychopharmacology (Berl). 2020 Mar;237(3):833-840. doi: 10.1007/s00213-019-05421-x. Epub 2019 Dec 12.</citation>
    <PMID>31832719</PMID>
  </reference>
  <reference>
    <citation>Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991 Sep;86(9):1119-27.</citation>
    <PMID>1932883</PMID>
  </reference>
  <reference>
    <citation>Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989 Sep;39(9):1159-65.</citation>
    <PMID>2771064</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Fan-Gang Zeng</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>nicotine</keyword>
  <keyword>biomarker</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

